Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
Imai H, Wasamoto S, Tsuda T, Nagai Y, Kishikawa T, Masubuchi K, Osaki T, Miura Y, Umeda Y, Ono A, Minemura H, Yamada Y, Nakagawa J, Kozu Y, Taniguchi H, Ohta H, Kasai T, Kaira K, Kagamu H. Imai H, et al. Among authors: masubuchi k. Thorac Cancer. 2023 Sep;14(25):2567-2578. doi: 10.1111/1759-7714.15036. Epub 2023 Jul 19. Thorac Cancer. 2023. PMID: 37469246 Free PMC article.
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
Nishihara-Kato F, Imai H, Tsuda T, Wasamoto S, Nagai Y, Kishikawa T, Miura Y, Ono A, Yamada Y, Masubuchi K, Osaki T, Nakagawa J, Umeda Y, Minemura H, Kozu Y, Taniguchi H, Ohta H, Kaira K, Kagamu H. Nishihara-Kato F, et al. Among authors: masubuchi k. Oncology. 2024;102(1):30-42. doi: 10.1159/000533604. Epub 2023 Aug 18. Oncology. 2024. PMID: 37598676
Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.
Wasamoto S, Imai H, Tsuda T, Nagai Y, Kishikawa T, Ono A, Masubuchi K, Umeda Y, Yamada Y, Nakagawa J, Yui T, Taniguchi H, Kaira K, Kagamu H. Wasamoto S, et al. Among authors: masubuchi k. Intern Med. 2024 May 16. doi: 10.2169/internalmedicine.3649-24. Online ahead of print. Intern Med. 2024. PMID: 38749728 Free article.
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial.
Iihara H, Iwai M, Morita R, Fujita Y, Ohgino K, Ishihara T, Hirose C, Suzuki Y, Masubuchi K, Kawazoe H, Kawae D, Aihara K, Endo S, Fukunaga K, Yamazaki M, Tamura T, Kitamura Y, Fukui S, Endo J, Suzuki A. Iihara H, et al. Among authors: masubuchi k. Lung Cancer. 2024 Apr 24;192:107801. doi: 10.1016/j.lungcan.2024.107801. Online ahead of print. Lung Cancer. 2024. PMID: 38678830 Free article.
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A, Takechi H, Shiihara J, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Kagamu H, Minato K. Masubuchi K, et al. Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5. Thorac Cancer. 2022. PMID: 36062426 Free PMC article.
156 results